Tamtam Try Tamtam free
LEO Pharma logo

LEO Pharma account plan

Dermatology research and development

At a glance

LEO Pharma is a Danish, privately held medical dermatology company with 2025 revenue of DKK 13,499 million and more than 4,000 employees in 30 countries.

LEO Pharma A/S is a Danish medical dermatology company, majority-owned by the LEO Foundation with Nordic Capital as co-owner since 2021. It sells more than 20 dermatology brands plus heparin-based Critical Care products in 70+ markets (31 affiliate and 42 partner markets), treating more than 100 million patients a year. In 2025 it reported revenue of DKK 13,499 million (EUR 1,809 million), +10% at CER, adjusted EBITDA of DKK 2,107 million (16% margin) and net profit of DKK 2,489 million. It had 4,265 FTE at year-end 2025 and 4,426 FTE at 30 September 2026. Revenue split in 2025 was Europe 52%, Rest of World 27% and North America 21%.

Business units

Strategic priorities

Global rollout of Anzupgo
Complete the launch and rollout of Anzupgo, then label extensions. It was launched in 12 markets with early access in 10 more by 9M 2026, approved in the EU for adolescents in October 2026 and in China for adults on 13 November 2026.
Spevigo integration and uptake
Fully integrate Spevigo and accelerate access, with the U.S., Japan and China as priority markets. Quarterly revenue rose from DKK 128 million in Q1 2026 to DKK 178 million in Q3 2026.
Build a rare genetic skin disease franchise
Acquired the Replay HSV gene therapy platform in April 2026 and dersimelagon from Tanabe Pharma in September 2026; the FDA granted Priority Review with a decision expected by end of February 2027, and LEO is preparing a potential U.S. launch in 2027.
Grow established brands through alliance markets
Alliance markets served through distribution and commercial partners are named as the key growth drivers for the established brands.
Partnership-led pipeline
R&D spending rises in 2026 for delgocitinib in lichen sclerosus (Phase 3 DELTA CARE 1, up to 652 patients) and palmoplantar pustulosis, spesolimab in pyoderma gangrenosum, and tralokinumab in pediatric atopic dermatitis.
2026 financial targets
Reaffirmed outlook: revenue growth 9-11% at CER, adjusted EBITDA margin 14-16%, free cash flow excluding BD&L above DKK 700 million, positive reported net profit.

Latest results

In the first nine months of 2026, revenue rose 9% to DKK 10,961 million, or 11% at CER (organic 7%); Q3 revenue was DKK 3,704 million, +12% at CER. North America was the fastest-growing region at DKK 2,673 million (+38% at CER), Rest of World grew 10% and Europe 1%. Gross margin rose to 65% (+4 points), but OPEX rose 22% to DKK 6,317 million on launches, the U.S. sales force and pipeline spending, so adjusted EBITDA fell to DKK 1,873 million (17% margin vs 21%). Net profit was DKK 679 million. Free cash flow was an outflow of DKK 1,057 million after DKK 2,131 million of BD&L payments, and leverage rose to 5.6x LTM adjusted EBITDA. The 2026 outlook was reaffirmed at 9-11% revenue growth at CER and a 14-16% adjusted EBITDA margin.

Investments and deals

Dersimelagon acquisition
Closed on 17 September 2026 for USD 275 million upfront, plus USD 160 million on FDA approval and tiered royalties; an oral MC1R agonist for EPP and XLP.
Replay gene therapy platform
Acquired on 30 April 2026 for USD 50 million upfront: a pre-clinical HSV gene therapy platform for genetic skin diseases, lead candidate in dystrophic epidermolysis bullosa.
Spevigo license
Global license from Boehringer Ingelheim, closed September 30, 2025, for EUR 90 million upfront; LEO's first entry into rare disease within dermatology.
Fucidin API facility in Ballerup
A new, fully automated Fucidin API facility opened in Ballerup on 10 September 2026.
U.S. commercial expansion
The U.S. sales force was expanded by more than 50% in 2025 to support the Anzupgo and Spevigo launches.

Challenges and risks

Margin pressure from launches and deals
OPEX rose 22% in 9M 2026 and the adjusted EBITDA margin fell to 17% from 21%; Replay and dersimelagon are expected to cost 2 points of 2026 margin, and dersimelagon will also weigh on 2027.
Higher leverage
Net interest-bearing debt reached DKK 10,438 million at 30 September 2026, with leverage at 5.6x LTM adjusted EBITDA versus 4.4x at year-end 2025.
Pricing and market access
The annual report names market access and pricing, including the U.S. Most-Favored-Nation executive order, tight healthcare budgets, tariffs and price reforms in the U.S. and China as key risks.
Flat established brands and soft Europe
Established brands were flat in 9M 2026, hit by a European distributor transition; Europe grew 1% at CER, with the UK, Italy and France declining.
Supply chain and cyber security
Supply chain disruption and IT and cyber security are listed among the key operational risks.

What leadership says

“We delivered a strong first nine months of 2026, reflecting the momentum we are building across our business. The global roll-out of Anzupgo® continues to expand and the uptake of Spevigo® is accelerating.”

Christophe Bourdon, CEO · LEO Pharma Nine-month interim report (9M) 2026, 16 November 2026

“While Europe has historically been a pharmaceutical heavyweight, we are now facing stagnation in our research pipeline and increasing competition from the US and the rapidly growing Chinese pharmaceutical industry.”

Christophe Bourdon, CEO · Insights Care interview, June 2025

“If medicine is not used, it is of no use.”

Frederik Kier, Executive Vice President International Operations · Gulf News Tell Me Why podcast, July 2026

Where a supplier can help

Launch support for Anzupgo and dersimelagon
With Anzupgo rolling out market by market and a potential U.S. launch of dersimelagon in 2027, suppliers of commercial launch, market access and medical education services fit the launch priorities.
Commercial efficiency under margin pressure
OPEX up 22% and a lower EBITDA margin make tools that raise sales force productivity in the expanded U.S. team relevant to the margin challenge.
Partner and distributor management
Alliance markets drive the established brands and a distributor transition hurt Europe, so partner management and distribution services tie to that priority and challenge.
Supply chain and manufacturing resilience
Supply chain disruption is a named risk and a new Fucidin API facility just opened, opening room for manufacturing, automation and supply planning suppliers.
Cyber security and AI tooling
Cyber security is a named risk and the company is adopting generative AI and its Innoviewer asset-scouting platform, which fits security and data providers.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like LEO Pharma?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about LEO Pharma

What does LEO Pharma do?

LEO Pharma is a Danish medical dermatology company selling treatments for skin diseases such as atopic dermatitis, chronic hand eczema and generalized pustular psoriasis, plus Critical Care anticoagulation products, in 70+ markets.

What is LEO Pharma's revenue?

2025 revenue was DKK 13,499 million (EUR 1,809 million), +10% at CER. In the first nine months of 2026 revenue was DKK 10,961 million, +11% at CER.

How many employees does LEO Pharma have?

More than 4,000 employees in 30 countries; 4,426 FTE at 30 September 2026.

Who owns and leads LEO Pharma?

It is majority-owned by the LEO Foundation, with Nordic Capital as co-owner. Christophe Bourdon has been CEO since 2022, and Jesper Brandgaard chairs the Board.

What is LEO Pharma's strategy?

Growth through three innovative brands (Adtralza/Adbry, Anzupgo, Spevigo), a partnership- and acquisition-led pipeline now extending into rare genetic skin disease, and improved profitability.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)